



# EXHIBIT 14



CONFIDENTIAL MATERIAL OMITTED AND  
FILED SEPARATELY WITH THE SECURI-  
TIES AND EXCHANGE COMMISSION.  
ASTERISKS DENOTE SUCH OMISSIONS

DEVELOPMENT AND LICENSE AGREEMENT

Between

BOEHRINGER MANNHEIM GMBH  
Sandhofer Strasse 116  
D-6800 Mannheim 31  
Federal Republic of Germany

(in the following referred to as "BM")

And

GENETICS INSTITUTE, INC.  
87 CambridgePark Drive  
Cambridge, Massachusetts 02140  
U.S.A.

(in the following referred to as "GI")

A 73220

TABLE OF CONTENTS

Introduction .....	4.
<u>Article 1. DEFINITIONS</u>	<u>Article</u>
1.1 Affiliate .....	5.1
1.2 Chugai.....	5.2
1.3 * .....	5.3
1.4 * .....	5.4
1.5 Chugai Research Project.....	5.5
1.6 Benchmark .....	5.6
1.7 COMECON Countries.....	5.7
1.8 Confidential Information.....	5.8
1.9 Effective Date .....	5.9
1.10 Final Benchmark .....	6.1
1.11 Know-How .....	6.2
1.12 Patent Rights .....	6.3
1.13 GMP Materials .....	<u>Article</u>
1.14 Government Regulatory Agency .....	7.1
1.15 Improvements .....	7.2
1.16 Licensed Compounds .....	7.3
1.17 Licensed Products .....	7.4
1.18 Net Sales .....	7.5
1.19 Party .....	7.6
1.20 Principal Investigator .....	<u>Article</u>
1.21 Project .....	8.1
1.22 Research Fee .....	8.2
1.23 Sole Technology .....	8.3
1.24 Territory .....	<u>Article</u>
1.25 Valid Claim .....	9.1
<u>Article 2. THE PROJECT</u>	9.2
2.1 General .....	9.3
2.2 Inspection .....	9.4
2.3 Laboratory Facilities .....	
2.4 Patent and Confidential Information Agreements.....	
2.5 Progress Reports .....	
2.6 Disclosure .....	
2.7 Flexibility .....	
2.8 Commercialization .....	
2.9 Completion of Benchmarks .....	
2.10 Arrangements with Third Parties .....	

*ll*

Article 3. PROJECT FUNDING

3.1 Research Fee .....7

3.2 Reimbursement of Additional Expenses .....8

Article 4. CONFIDENTIAL INFORMATION

4.1 Treatment of Confidential Information .....8

4.2 Release from Restrictions .....8

4.3 Publications .....9

Article 5. INTELLECTUAL PROPERTY RIGHTS

5.1 Sole Technology .....9

5.2 Licensee Technology .....9

5.3 Joint Technology .....9

5.4 Improvements .....10

5.5 Responsibility for Protection of Technology .....10

5.6 Right of BM to Prosecute Applications .....10

5.7 Mutual Assistance .....11

5.8 Infringement .....11

5.9 Claimed Infringement .....13

5.10\* .....14

Article 6. PATENT AND KNOW-HOW LICENSES

6.1 Patent Licenses .....14

6.2 Know-How Licenses .....15

6.3 Sublicenses .....15

Article 7. PATENT AND KNOW-HOW ROYALTIES

7.1 Royalties .....15

7.2 Minimum Royalty .....16

7.3 Reports and Payment .....16

7.4 Certain Foreign Royalties .....17

7.5 Records .....17

7.6 Dominant Patents .....17

Article 8. MANUFACTURING RIGHTS

8.1 Pre-Commercialization Rights .....17

8.2 Commercial Supply of Licensed Products .....18

8.3 Technical Assistance .....18

Article 9. TERMINATION

9.1 Term .....19

9.2 Termination for Breach .....19

9.3 Termination by GI of Exclusivity .....19

9.4 Survival of Obligations; Return of Confidential Information .....20

*66-304*

Article 10. MISCELLANEOUS

10.1 Product Liability Indemnification.....  
 10.2 Publicity .....  
 10.3 Assignment .....  
 10.4 Governing Law.....  
 10.5 Force Majeure.....  
 10.6 Waiver .....  
 10.7 Notices .....  
 10.8 No Agency.....  
 10.9 Entire Agreement.....  
 10.10 Headings .....  
 10.11 Severability .....  
 10.12 Successors and Assigns.....  
 10.13 Counterparts.....

SCHEDULE A Benchmarks  
 SCHEDULE B Territory  
 SCHEDULE C COMECON Countries  
 SCHEDULE D Minimum Royalty  
 SCHEDULE E Bonus Payment  
 SCHEDULE F Pre-Commercialization Supply of Licensed Compound  
 SCHEDULE G Production Schedule

AGRE  
 INSTITUTE  
 Place of  
 Massachusetts  
 or  
 principal  
 Mannheim  
 referred

INTRODUCT

1. GI  
 and  
 assi  
 conc  
 of 1  
 to  
 recd  
 proc  
 2. BM  
 with  
 uti  
 ery  
 in  
 nat  
 sub  
 wil  
 3. GI  
 for  
 fac  
 Kno  
 per



In cons  
 containe  
 consider

As used  
 in the s

AGREEMENT dated as of October 8, 1985 between GENETICS INSTITUTE, INC., a Delaware corporation, having its principal place of business at 87 CambridgePark Drive, Cambridge, Massachusetts 02140, U.S.A. (hereinafter referred to as "GI"), and BOEHRINGER MANNHEIM GMBH, a corporation having its principal place of business at Sandhofer Strasse 116, D-6800 Mannheim 31, Federal Republic of Germany, (hereinafter referred to as "BM").

INTRODUCTION

GI has and maintains research and development facilities and experienced scientists, research associates and assistants and other personnel which enables it to conduct research and development activities in the area of recombinant DNA technology and the application thereof to the development, production and processing of recombinant DNA and to the production and expression of products using that technology.

Licensed

BM desires that GI, on behalf of and in collaboration with BM, undertake a research and development project utilizing recombinant DNA technology for producing erythropoietin on a commercially feasible basis for use in humans. In return for certain rights under the patents and know-how developed by GI, BM will financially support the research and development activities of GI and will pay GI the royalties provided for herein.

GI is willing, for the consideration and on the terms set forth herein, to use its research and development facilities and scientists as well as GI patents and know-how, research associates and technicians and other personnel to conduct the Project (as defined below).

In consideration of the mutual covenants and promises contained in this Agreement and other good and valuable considerations, GI and BM agree as follows:

Article 1. Definitions

As used in this Agreement, the following terms, whether used in the singular or plural, shall have the following meanings:

*Li Bo*

1.1 "Affiliate" means any corporation, partnership, joint venture and/or firm which controls, controlled by or is under common control with either Party with either Party's shareholders; without limiting the generality of the foregoing, control shall mean:

- a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares entitled to vote for the election of directors, and
- b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to direct the management and policies of such non-corporate entities.

1.2 "Chugai" shall mean Chugai Pharmaceutical Co. Ltd. with whom GI has entered into an agreement relating to the development of erythropoietin.

1.3\*

1.4\*

1.5 "Chugai Research Project" shall mean the research program conducted by GI and Chugai pursuant to the terms of the agreement dated as of June 29, 1984.

1.6 "Benchmarks" shall mean the sequential research and development steps of the Project, as set forth in Schedule A to this Agreement.

1.7 "COMECON Countries" shall mean the countries and territories specified in Schedule C hereto.

1.8 "Confidential Information" shall mean know-how defined in Section 1.11 below, and any other information designated by the disclosing party as confidential or proprietary, whether or not related to the production or expression of Licensed Compound and/or Licensed Products.

1.9 "Effective Date" shall mean the date on which this agreement is executed and completely signed by both parties.

1.10 "Final Benchmark" shall mean the last of the sequential research and development steps of the Project set forth in Schedule A hereto.

1.1  
pat.  
producti  
erythrop  
products  
informat  
enable E  
Licensed

a)

b)

1.  
Territo  
World  
to anal  
or Lic  
conti  
extens:

1  
the st.  
in que  
agreed  
Benchm:

1  
governr  
respon:  
market:

1  
or not  
during  
in the

on, company, controls, either Party limiting the

s, direct percent (50%) vote for the

es, direct percent (50%) to direct the non-corporate

ical Co. Ltd. relating to the

the research the terms of

l research in Schedule 1

countries

n Know-how or information confidential production Products.

on which other parties.

last of the Project

1.11 "Know-How" shall mean all technical information of GI, patentable or otherwise, relating to the expression and production of erythropoietin, the cloning of genes coding for erythropoietin or precursors thereof, and/or procedures and products used in developing such a cloned gene, which information is used by GI in the Project and is required to enable BM to manufacture and/or sell the Licensed Compound or Licensed Product, including without limitation:

- a) such information which is licensed or sublicensed to or obtained by GI including (to the extent that GI is entitled to license or sublicense such information to others); and
- b) all inventions, cell sources, cultures, strains, organisms and parts thereof, plasmids, clones, vectors, progeny, derivatives and parts thereof, formulae, methods, procedures, processes, materials, reagents, components, equipment, equipment design, animal studies, clinical or other evaluations, analytical results, and quality control or safety procedures which have been, are or shall be developed, isolated, purified, constructed or improved by GI relating to the production, use or manufacture of the Licensed Compound and/or to the development of cloned genes coding for erythropoietin or precursors thereof.

1.12 "Patent Rights" shall mean all patent rights in the Territory and all patents throughout the world based on subject matter used in the Project and required to enable BM to manufacture and/or sell the Licensed Compound or Licensed Product, including any additions, divisions, continuations, continuations-in-part, substitutions, extensions, renewals or reissues thereof or therefore.

1.13 "GMP Materials" shall mean erythropoietin meeting the standards of "good manufacturing practice" and sufficient quality for use in connection with clinical trials, as agreed upon by the parties separately before conclusion of Benchmark II.

1.14 "Government Regulatory Agency" shall mean the governmental agency in each country in the Territory responsible for reviewing and approving the development or marketing of Licensed Products.

1.15 "Improvements" shall mean any information, whether or not patentable, developed or acquired by either Party during the term of this Agreement which is used by such party in the manufacture of Licensed Compound. With regard to GI,

*Handwritten initials/signature*

A 73226



the term "Improvements" shall refer only to information developed or acquired by GI following the completion of the Final Benchmark.

With regard to BM, "Improvement" shall mean information directly related to the established product Licensed Compound at BM's facilities and developed after the establishment.

1.16 "Licensed Compounds" shall mean any and all human erythropoietin consisting of

which, is covered by a Valid Claim of any of the Patent and/or embodies any Know-how.

1.17 "Licensed Products" shall mean any and all formulations, mixtures and/or compositions for whatever which contain Licensed Compound.

1.18 "Net Sales" shall mean the amount (exclusive of value added taxes) by BM to wholesalers or users of Licensed Products and Licensed Compounds, less a lump sum of \* to cover all usual deductions such as credits for returns, cash, trade or other discounts, transportation charges, allowances, etc.

In case of distribution of the Licensed Products by Affiliates or sublicensees of BM, Net Sales shall have the meaning as defined above.

For countries where BM is only represented by unrelated distributors supplied by BM with finished goods, the royalty shall be calculated on BM's Net Sales to such distributor.

Net Sales shall not include any transfer between BM or any of its Affiliates or sublicensees for resale but shall include the resale from an Affiliate or sublicensee to an independent third party or use by the Affiliate or sublicensee.

Any commercial use of the Licensed Compounds or Licensed Products by BM, its Affiliates or sublicensees in a commercial transaction with a third party, in which no invoice is issued shall be considered a sale hereunder for royalty accounting purposes and Net Sales for such use shall be the average price of arms' length sales by BM, its Affiliates or sublicensees during the royalty reporting period in which such use occurs, or if no such sales occurred in such period, the last period in which such arms' length sales occurred.

1.19 "Party" shall mean GI or BM; "Parties" shall mean GI and BM".

1.20 "Principal Scientist, Researcher or any other Person"

1.21 "Project" shall mean the effect of the Final Benchmark and performed as well as recombinant DNA.

1.22 "Recombinant DNA" shall mean the Project in accordance with the Project.

1.23 "Secret Information"

1.24 "Trade Secret" shall mean as specified in the Project.

1.25 "Valid Claim" shall mean a patent or intellectual property right which has not been withdrawn, abandoned, or otherwise unenforceable or unappealable.

2.1 "Gantt Chart" shall mean a chart contained in the Project, the Date, to which the objective of the Project is set forth in the Gantt Chart.

2.2 "Laboratory" shall mean the laboratory or laboratories arranged for the Project in detail in the Project, other than the business operations of the Project.

2.3 "Suitable Laboratory" shall mean a laboratory suitable to perform the Project.

2.4 "Scientist" shall mean a scientist, researcher and technician who is a party to the Project Agreement.

A 73227

o information  
lection of the  
ll mean only  
production of  
ed after their  
nd all kinds of  
ing or use of  
e Patent Rights  
nd all kinds of  
r whatever  
mount invest  
esalers or fir  
ds, less on  
ual deductio  
other discou

1.20 "Principal Investigator" shall mean the senior scientist, responsible vice president for process development, or any other person agreed upon between the parties.  
1.21 "Project" shall mean the research program commencing on the effective date and terminating with the completion of the Final Benchmark conceived, planned, organized, controlled and performed by GI for development of production technology as well as manufacture of Licensed Compound by means of recombinant DNA following the latest standard of science and art.  
1.22 "Research Fee" shall mean the agreed upon cost of the Project to be paid by BM to GI in the manner and in accordance with the schedule set forth in Article 3 hereof.  
1.23 "Sole Technology" is defined in Section 5.1 hereof.  
1.24 "Territory" shall mean the countries and territories specified in Schedule B and C hereto.  
1.25 "Valid Claim" shall mean a claim of an unexpired patent or inventor's certificate which shall not have been withdrawn, cancelled or disclaimed, nor held invalid by a court of competent jurisdiction in an unappealed or appealable decision.

Article 2 THE PROJECT

sed Products  
shall have  
ted by unrel  
s, the roval  
distributors  
r between an  
resale but  
ublicenses  
Affiliate  
ounds or  
s in a com  
nvoice is  
for roval  
use shall  
Affiliate  
id in wh  
such mark  
les occur  
ies shall

2.1 General. Subject to the terms and conditions contained in this Agreement, GI agrees, as of the Effective Date, to undertake the Project on a best efforts basis, with the objective of completing each Benchmark and/or assisting BM in the completion of each Benchmark, as the case may be.  
2.2 Inspection. Each Party shall have the right to engage for its employees and outside consultants involved in the Project to visit the other Party at its offices and laboratories, and to discuss the Project work and its results in detail with the technical personnel and consultants of the other Party, provided that such visits shall be during normal business hours and shall not unreasonably interrupt the operations of the other Party.  
2.3 Laboratory Facilities. GI agrees to furnish suitable laboratory facilities and equipment for the work to be performed in connection with the Project.  
2.4 Patent and Confidential Information Agreements. GI shall require the Principal Investigator, and all GI employees, research associates and assistants, technicians and technical personnel assigned to the Project to execute an agreement for the assignment of inventions and for the

66-30

A 73228

protection of Know-How and Confidential Information in the reasonable form as may from time to time be used by GI for such purpose.

BM shall require all scientific and other employees working on or involved in the Project, to be similarly bound by written agreement.

**2.5 Progress Reports.** Each Party shall provide the other Party with written progress reports summarizing technological, clinical testing and marketing progress of the Project within 30 days after the end of each six month period, starting with January 1, 1986.

For a six months period in which a Benchmark is completed the report of the applicable Party will include a final report on the attainment of such Benchmark.

**2.6 Disclosure.** GI shall disclose all Know-How as well as the production clone in confidence to BM 30 days following the signature of the Agreement or immediately after obtaining them to enable BM to manufacture and produce Licensed Compounds as well as Licensed Products.

BM shall disclose in confidence to GI all animal studies, human studies and other tests or submissions to Government Regulatory Agencies arising from the Project, after having obtained such data, results and documents. GI may utilize such information outside the Territory only if agreed upon in writing between the Parties case by case.

**2.7 Flexibility.** In carrying out the research which GI will conduct in the course of the Project, GI shall have and maintain sufficient flexibility to shift effort and emphasis within the overall scope of such Project in a manner that will, in the opinion of the Principal Investigator, after consultation with and giving due consideration to the advice of BM, best result in the development of useful technology for the production of the Licensed Compound.

**2.8 Commercialization.** Promptly and diligently after GI's supply of GMP-material in an amount of at least 100 grams, BM shall exert its best efforts, at its own expense, to:

- a) undertake and complete preclinical developments and the formulations to be used for clinical trials;
- b) conduct all necessary and appropriate animal and human testing and clinical trials on the Licensed Products, and control the manner and extent of such testing;
- c) provide for commercial scale production of Licensed Products;

d) F  
e) F

2.9  
completion  
Benchmark  
of such  
sufficient  
such other  
Such other  
Benchmark

2.10  
right to  
performanc  
for the P  
provided  
comment o  
is GI in  
Affiliate  
commercial  
production  
Schedule  
Appro  
withheld.  
such execu

3.1  
developme  
regard to  
the amount  
Schedule  
non-refur  
Paym  
such bene

A 73229

nation in such  
used by GI for

ther employees  
similarly bound

l provide the  
ummarizing the  
progress of the  
ach six months

rk is completed  
a final report

now-How as well  
days following  
after obtaining  
icensed Compound

animal studies  
s to Government  
t, after having  
GI may utilize  
f agreed upon

research which  
I shall have  
ort and employ  
n a manner  
estimator, after  
on to the adv  
al technical

diligently  
at least  
xpense, to

developments  
nical trans

riate animal  
on the  
nd expense

roduction

- d) prepare, file and prosecute all governmental applications for approvals necessary to produce, manufacture, distribute and market the Licensed Products in the Territory; and
- e) market the Licensed Products in the Territory on a diligent commercial basis after approval by the applicable Government Regulatory Agency.

BM shall provide information to GI upon its reasonable request as to the status of its commercialization efforts under subsections a) through e) above.

**2.9 Completion of Benchmarks.** Promptly after the completion of each Benchmark, the Party completing such Benchmark (the "Notifying Party") shall notify the other Party of such completion and shall provide to such other Party sufficient written materials and samples in order to permit such other Party to evaluate completion of such Benchmark. Such other Party shall comment on the completion of such Benchmark within 45 days after receipt of such notice.



**2.10 Arrangements with Third Parties.** GI shall have the right to contract with third parties approved by BM for the performance of work in connection with the Project, as well as for the production of Licensed Compound for commercial use, provided that BM shall have the opportunity to review and comment on any such proposed contract prior to its execution. If GI intends to contract with third parties who are not affiliates of GI, the production of Licensed Compound for commercial use, then BM reserves the right to take over such production as set forth in this Agreement. In this event, Article G does not apply.

Approval of any such contract shall not be unreasonably withheld. GI will provide BM with a complete copy of each executed contract.

**Article 3. PROJECT FUNDING**

**3.1 Research Fee.** In consideration of the research, development and related activities undertaken by GI with respect to the Project, BM shall pay to GI the Research Fee in the amount and in the periodical installments set forth in Schedule A below, all such amounts to be firm and non-refundable.

Payments for each Benchmark shall be due only in case the Benchmark is satisfactorily completed.

Handwritten initials "L. Be" in the bottom right corner.

3.2 Reimbursement of Additional Expenses. In the event that the transfer of technology from GI to BM to produce the License Compound in quality as agreed upon exceeds the projected time and cost budget as described in Article 1, then GI shall be reimbursed by BM for its additional expenses to be agreed upon in writing case by case. GI shall keep the and accurate records to substantiate all Additional Expenses invoiced to BM, including the date incurred and the nature thereof. Upon request from BM, GI shall permit BM or its authorized representatives to inspect such records in confidence in order to verify the amount of Additional Expenses invoiced hereunder.

Article 4. CONFIDENTIAL INFORMATION

4.1 Treatment of Confidential Information. Each Party hereto shall maintain the Confidential Information of the other Party in confidence, and shall not disclose, divulge, otherwise communicate such Confidential Information to others or use it for any purpose, except pursuant to, and in order to carry out, the terms and objectives of this Agreement. Each Party hereby agrees to exercise every reasonable precaution to prevent and restrain the unauthorized disclosure of its Confidential Information by any of its directors, officers, employees, consultants, subcontractors, sublicensees or agents.

4.2 Release from Restrictions. The provisions of Section 4.1 shall not apply to any Confidential Information disclosed hereunder which:

- a) was known or used by the receiving Party prior to its date of disclosure to the receiving Party, as evidenced by the prior written records of the receiving Party; or
- b) either before or after the date of the disclosure to the receiving Party is lawfully disclosed to the receiving Party by an independent, unaffiliated third party rightfully in possession of the Confidential Information; or
- c) either before or after the date of the disclosure to the receiving Party becomes published or generally known to the public through no fault or omission on the part of the receiving Party or its Affiliates; or
- d) the receiving Party is required to disclose, to comply with applicable laws, to defend or prosecute litigation or to comply with governmental regulations, provided that the receiving Party provides prior written notice of such disclosure to the

the  
action  
disc  
4.3 Publi  
sely with Resp  
lications by  
Party relating  
project:

a) A Pa  
othe  
publ  
such  
oppo  
heli  
Know  
and  
sha:

b) If  
wit  
pro  
rea  
mat  
Knc  
the  
del  
the  
su:  
an  
ti:  
in

A

5.1 Sc  
title and i  
developed  
(hereinafter

5.2 L  
title and i  
and Know-  
consultants  
Products an

5.3  
Particular  
right, tit  
rights in  
to practic  
the Project

In the event  
to produce the  
exceeds the  
Article 8.3,  
onal expenses  
all keep true  
onal Expenses  
nd the nature  
it BM or its  
records in  
of Additional

Each Party  
ation of the  
se, divulge or  
ion to others,  
nd in order to  
greement, and  
precaution to  
sure of such  
ors, officers,  
licensees

provisions --  
al Informati--

Party prior to  
ing Party, as  
ords of the

disclosure to  
closed to the  
unaffiliated  
sion of the

disclosure to  
i or general  
or omission  
ts Affiliated

disclosure  
d or prosecute  
governmental  
ceiving part  
disclosure

the other Party and takes reasonable and lawful actions to avoid and/or minimize the degree of such disclosure.

4.3 Publications. The following restrictions shall apply with respect to the disclosure in scientific journals or publications by any Party or any employee or consultant of any Party relating to any scientific work performed as part of the Project:

- a) A Party (the "Publishing Party") shall provide the other Party with an advance copy of any proposed publication of results arising from the Project, and such other Party shall have a reasonable opportunity to recommend any changes it reasonably believes are necessary to preserve Patent Rights or Know-How belonging in whole or in part to GI or BM, and the incorporation of such recommended changes shall not be unreasonably refused; and
- b) If such other Party informs the Publishing Party, within 30 days of receipt of an advance copy of a proposed publication, that such publication in its reasonable judgment could be expected to have a material adverse effect on any Patent Rights or Know-How belonging in whole or in part to GI or BM, the Publishing Party shall use its best efforts to delay or prevent such publications as proposed. In the case of inventions, the delay shall be sufficiently long to permit the timely preparation and filing of a patent application(s) or application(s) for a certificate of invention on the information involved.

Article 5. INTELLECTUAL PROPERTY RIGHTS

5.1 Sole Technology. GI shall own the entire right, title and interest in and to all Patent Rights and Know-How developed solely by employees or consultants of GI (hereinafter "Sole Technology").

5.2 Licensee Technology. BM shall own the entire right, title and interest in and to all patents, patent applications and Know-How of BM developed solely by employees or consultants of BM at any time which relate to Licensed Products and/or the Licensed Compound.

5.3 Joint Technology. Unless otherwise agreed in particular instances, the Parties shall own jointly the entire right, title and interest in and to all patent and other rights in any product, method or apparatus conceived, reduced to practice or developed jointly by GI and BM in the course of the Project (hereinafter "Joint Technology").

*lit* *Bo*

A 73232

5.4 Improvements. To the extent that the Party... develop an Improvement or otherwise acquire the right to... a license covering any Improvements, each Party grants to the other a nonexclusive, non-transferable license, to make, use and sell such Improvements solely in connection with the manufacture of Licensed Compound for the Territory in the Party's and its Affiliates' production facilities.

5.5 Responsibility for Protection of Technology.

- a) Except as otherwise provided in this Agreement, each Party shall have the responsibility on its own account to:
  - (i) maintain patent protection in any country within the Territory on any Sole Technology;
  - (ii) file for, procure and maintain patents in any country within the Territory on such Sole Technology; and
  - (iii) protect and enforce in the Territory patents issued on any Sole Technology, subject to Section 5.8 below.
- b) Copies of all substantive communications to and from the United States and foreign patent offices regarding applications, patents or certificates of invention on any Sole Technology shall be provided to the other Party promptly after the receipt thereof; copies of proposed substantive communications to such patent offices shall, if practicable, be provided to the other Party sufficient time before the due date in order to enable the other Party to comment on the content thereof.

5.6 Right of BM to Prosecute Applications. If GI elects not to seek or continue to seek, use or maintain patent protection on any Sole Technology in any country within the Territory, BM shall have the right to file, procure, maintain and enforce in such countries patents on such Sole Technology. GI agrees to advise BM of all decisions taken under Section 5.5 (a) i)-iii) in a timely manner in order to allow BM to protect its rights under this Section 5.6.

If GI elects not to file a patent application or application for a certificate of invention, not to maintain a patent or certificate of invention, or to abandon a pending patent application or application for a certificate of invention, GI shall advise BM, and BM shall have the right, but not the obligation, to file such application, maintain such patent or certificate of invention or continue to attempt to obtain protection on the subject matter disclosed in such pending application. GI shall pay the reasonable expenses of such activities for the countries A listed in Schedule B.

5.7 Mu... to the other... ments of... other Party... order to as... the Sole Te... Each... signed all... patent app... invention o... convention at

5.8 IR

A 73233



the Parties  
right to grant  
rights to the  
to make, use  
in with the  
copy in the

ogy.

reement, GI  
own account.

any country  
echnology;

tents in any  
such Sole

rritory and  
ogy, subject

to and from  
es regardi-  
of invent-  
vided to as  
copies of  
such patent  
ded to BM  
in order to  
eef.

If GI elects  
ntain patent  
y within the  
ire, maintain-  
echnology  
der Section  
allow BM to

plication of  
o maintain  
on a pending  
tificate  
e the right  
on, mainte-  
e to attend  
osed in such  
expenses  
odule A.

5.7 Mutual Assistance. Each Party shall make available to the other Party or its respective authorized attorneys, agents or representatives, such of its employees whom the other Party in its reasonable judgment deems necessary in order to assist such Party in obtaining patent protection for the Sole Technology and Joint Technology.

Each Party shall sign or use its best efforts to have assigned all legal documents necessary to file and prosecute patent applications or applications for certificates of invention or to obtain or maintain patents or certificates of invention at no charge to the other Party.

5.8 Infringement.

a) Each Party shall promptly report in writing to the other Party during the term of this Agreement any (i) known infringement or suspected infringement of any of the Patent Rights, or (ii) unauthorized use or misappropriation of Know-How or Confidential Information by a third party of which it becomes aware, and shall provide the other Party with all available evidence supporting said infringement, suspected infringement or unauthorized use or misappropriation.

b) Except as provided in paragraph d) below, GI shall have the right to initiate an infringement or other appropriate suit anywhere in the Territory against any third party who at any time has infringed or is suspected of infringing, any of the Patent Rights or of using without proper authorization all or any portion of the Know-How. GI shall give BM sufficient advance notice of its intent to file said suit and the reasons therefor, and shall provide BM with an opportunity to make suggestions and comments regarding such suit. GI shall keep BM promptly informed, and shall from time to time consult with BM regarding the status of any such suit and shall provide BM with copies of all documents filed in, and all written communications relating to, such suit.

c) GI shall have the sole and exclusive right to select counsel for any suit referred to in paragraph b) above and shall, except as provided below, pay all expenses of the suit, including without limitation attorney's fees and court cost.

Handwritten initials and marks, including "BC" and "HS".

A 73234



BM, in its sole discretion, may elect within 60 days after the commencement of litigation, to contribute to the costs incurred by GI in connection with litigation and, if it so elects, any damages, royalties, settlement fees or other consideration received by GI, its Affiliates or sublicensees as a result of such litigation shall be shared by BM and GI pro rata their respective sharing of the costs of such litigation. In the event that BM elects not to contribute to the costs of such litigation, GI and/or its Affiliates shall be entitled to retain any damages, royalties, settlement fees or other consideration resulting therefrom. If necessary, BM shall join as a party to the suit but shall be under no obligation to participate except to the extent that such participation is required as the result of being named party to the suit. BM shall offer reasonable assistance to GI in connection therewith at no charge to GI except for reimbursement of reasonable out-of-pocket expenses, including salaries of BM personnel incurred in rendering such assistance.

BM shall have the right to participate and be represented in any such suit by its own counsel at its own expense. GI shall not settle any such suit involving rights of GI without obtaining the prior written consent of BM, which consent shall not be unreasonably withheld.

d) In the event that GI elects not to initiate an infringement or other appropriate suit pursuant to paragraph b) above, GI shall promptly advise BM of its intent not to initiate such suit, and BM shall have the right to initiate an infringement or other appropriate suit against any third party who at any time has infringed, or is suspected of infringing, any of the Patent Rights or using without proper authorization all or any portion of the Know-How.

If BM decides in good faith and after consultation with GI to initiate such suit



*Handwritten initials and scribbles.*

5.9 C1

a)

A 73235



elect within  
nt of such  
the costs  
with such  
any damages,  
or other  
is Affiliates  
ch litigation  
o rata their  
sts of such  
M elects not  
h litigation,  
a entitled to  
ttlement fees  
g therefrom,  
party to the  
blication to  
nt that such  
he result of  
M shall offer  
n connection  
except for  
out-of-pocket  
BM personnel  
ance.

icipate and to  
by its own  
GI shall ...  
rights of ...  
en consent of  
unreasonab...

to initiate a  
ropriate suit  
e, GI shall  
stant not to  
all have the  
ent or cons  
ird party  
suspected  
Rights of  
on all of

h and  
m such

llt 25

In exercising its rights pursuant to this paragraph d), BM shall have the sole and exclusive right to select counsel and, except as provided below, shall pay all expenses of the suit including, without limitation attorney's fees and court costs. Any damages, royalties, settlement fees or other consideration received by BM as a result of such litigation shall be shared by GI and BM pro rata their respective sharing of the costs of such litigation.

If necessary, GI shall join as a party to the suit but shall be under no obligation to participate except to the extent that such participation is required as a result of being a named party to the suit. At BM's request, GI shall offer reasonable assistance to BM in connection therewith at no charge to BM except for reimbursement of reasonable out-of-pocket expenses, including salaries of GI's personnel, incurred in rendering such assistance.

GI shall have the right to participate and be represented in any such suit by its own counsel at its own expense. BM shall not settle any such suit involving rights of GI without obtaining the prior written consent of GI, which consent shall not be unreasonably withheld.

5.9 Claimed Infringement.

- a) In the event that a third party at any time brings suit against BM, its Affiliates or sublicensees anywhere in the Territory claiming infringement of its patent rights or unauthorized use or misappropriation of its technology, based on a claim arising out of

llt H.S.B.

the manufacture, use or sale by BM, its Affiliates or sublicensees of Licensed Products, BM shall have the sole and exclusive responsibility for the selection of counsel and the control of the suit, and shall keep GI informed of the current status of the suit.

b) BM shall, after receipt of notification of a third party claim or notice of commencement of any action, suit or proceeding of the type described in paragraph a) above, notify GI of such claim or the commencement of said action, suit or proceeding, enclosing a copy of all papers served. GI may participate in the conduct of the suit at its own expense.

5.10



Article 6. PATENT AND KNOW-HOW LICENSES

6.1 Patent Licenses. Subject to the payment of the royalty provided in Article 7 and the fulfillment of the other terms and conditions of this Agreement, GI hereby grants to BM and its Affiliates an exclusive license in the Territory under the Patent Rights, including the right to grant sublicenses for the sole and exclusive purpose of manufacturing, having manufactured for BM and its Affiliates, using and selling Licensed Products as well as Licensed Compound in the Territory, provided however, that such license insofar as it pertains to the manufacturing of Licensed Compound is subject to the provisions and limitations of Article 8 herein. It is provided further that the foregoing licenses shall be applicable to COMECON Countries but only to the extent that BM, its Affiliates and/or sublicensees sell, supply or otherwise provide Licensed Products in final, finished form to such COMECON Countries and not any information, Know-How or other data pertaining to the development, manufacture, production of Licensed Products or Licensed Compound. Licenses granted pursuant to this Section 6.1 shall continue in effect until the expiration of the last Patent Right licensed to BM hereunder.

6.2  
royalty p  
terms and  
and its A  
the Terri  
the sole  
manufactu:  
Licensed  
provided  
the manu  
provision:  
further t  
COMECON  
Affiliate:  
provide I  
COMECON C  
data part  
of License

6.3  
sublicense

7.1

y BM, its  
Licensed  
d exclusive  
of counsel  
all keep GI  
he suit.

ation of a  
encement of  
f the type  
otify GI of  
aid action,  
opy of all  
ite in the  
nse.

6.2 Know-How Licenses. Subject to the payment of the royalty provided in Article 7 and the fulfillment of the other terms and conditions of this Agreement, GI hereby grants to BM and its Affiliates an exclusive license to use the Know-How in the Territory, including the right to grant sublicenses, for the sole and exclusive purpose of manufacturing, having manufactured for BM and its Affiliates, using and selling Licensed Products and Licensed Compound in the Territory, provided however, that such license insofar as it pertains to the manufacturing of Licensed Compound is subject to the provisions and limitations of Article 8 herein, and provided further that the foregoing licenses shall be applicable to COMECON Countries but only to the extent that BM, its Affiliates and/or sublicensees sell, supply or otherwise provide Licensed Products in final, finished form in such COMECON Countries and not any information, Know-How or other data pertaining to the development, manufacture or production of Licensed Products, or Licensed Compound.

6.3 Sublicenses. GI shall be informed by BM of each sublicense granted.

Article 7. PATENT AND KNOW-HOW ROYALTIES

7.1 Royalties

a) BM shall pay to GI \*

nt of the  
f the other  
ants to BM  
itory under  
ublicenses.  
ng, having  
nd selling  
d in the  
ofar as it  
is subject  
erein, and  
shall be  
extent that  
supply of  
ed form of  
know-How of  
acture, of  
ound. The  
l continue  
ent Right

on  
all Net Sales made in the Territory by BM, its Affiliates and sublicensees of Licensed Products and Licensed Compound which involve a valid claim under the Patent Rights. Royalties shall be payable on a country by country basis with respect to Net Sales in each country of the Territory where there is a Valid Claim under Patent Rights, and in each country where the Licensed Products or Licensed Compound being sold were manufactured or are to be used in which there is a Valid Claim under Patent Rights.

b) BM shall pay to GI earned royalties of \* based on all Net Sales anywhere in the Territory by BM, its Affiliates and sublicensees of Licensed Products or Licensed Compound which embody or utilize any of the Know-How. Royalties shall be payable under this subparagraph b) on a country by country basis for a period of \* after \*

*Handwritten signature/initials*

c) Under no circumstances shall BM be obligated to pay royalties under both paragraphs a) and b) above; only one royalty shall be payable and due regardless how many patent rights are involved.

7.2 Minimum Royalty. Beginning with \*

BM shall pay to GI the minimum annual royalty set forth in Schedule D hereof provided that for the calendar year in which the minimum royalty commencement date occurs, the minimum annual royalty due shall be proportionately adjusted if the minimum royalty period for such year is less than the full calendar year.

\*

In the event that the minimum annual royalties for a calendar year exceed the actual earned royalties for such calendar year, the difference between these amounts shall be due and payable within 60 days after the end of such calendar year.

Amounts by which earned royalties in any such year exceed the minimum royalty for such year shall not be credited against the minimum royalty due in any subsequent year, but may be set off against the minimum royalty due in the preceding year.

7.3 Reports and Payment. BM shall deliver to GI within 60 days after the end of each calendar quarter a written report showing its computation of royalties due under this Agreement upon Net Sales by BM, its Affiliates and its sublicensees during such calendar quarter. All Net Sales shall be segmented in each such report according to sales by BM, each Affiliate and each sublicensee, as well as on a country-by-country basis, including the rates of exchange used to convert such royalties into U.S. dollars from the currency in which such sales are made. For the purpose hereof, the rates of exchange to be used for converting royalties hereunder into U.S. dollars shall be the dollar rate officially in effect in the relevant country of the Territory at the date royalty payments are due and as shown in each royalty report.

BM, simultaneously with the delivery of each such report shall tender payment in U.S. dollars of all royalties shown to be due thereon.

Any withholding tax shall be deducted by BM, provided that BM shall use its best efforts to obtain exemption from withholding tax to the extent such exemption is available. BM shall advise GI in advance of such withholding possibility in order for GI to assist if necessary in obtaining such exemption.

to GI where, it is public in the current the tr bank i

7 Affili books and da rovalt date o Agreem termin to tim inspec

7 undert. Produc The pa provis: Affilia exploit in any without one or in the Compoun country on Net year pe

8. Affilia the ent galenic non-com Products: clinical commerc: Schedule

A 73239

obligated  
the a) and  
be payable  
rights are

to GI the  
D hereto,  
e minimum  
il royalty  
im royalty  
year.

s for any  
for such  
shall be  
1 calendar  
ear exceed  
credited  
year, but  
e in the

GI within  
a written  
nder this  
and any  
Net Sales  
sales by  
as on a  
range used  
currency  
proof, the  
royalties  
lar rate  
Territory  
in each

h report  
shown to  
provided  
tion from  
able. It  
bility  
and cost

7.4 Certain Foreign Royalties. Where royalties are due to GI hereunder for sales of Licensed Products in a country where, by reason of currency regulations or taxes of any kind, it is impossible or illegal for BM, its Affiliates or sublicensees to transfer royalty payments to GI for Net Sales in that country, such royalties shall be deposited in whatever currency is allowable by the person or entity not able to make the transfer for the benefit or credit of GI in an accredited bank in that country that is acceptable to GI.

7.5 Records. BM shall keep, and shall require all affiliates and sublicensees to keep, full, true and accurate books of accounts and other records containing all information and data which may be necessary to ascertain and verify the royalties payable hereunder for a period of 7 years from the date of creation of each such record. During the term of this agreement and for a period of one year following its termination, GI shall have the right at its expenses from time to time (not to exceed twice during each calendar year) to inspect, or have an agent, accountant or other representative inspect, such books, records and supporting data.

7.6 Dominant Patents. The Parties recognize that the undertaking of the Project and the marketing of Licensed Products involves some degree of risks of patent infringement. The parties wish to share such risk in accordance with the provisions of this Section 7.6. Accordingly, if BM, its affiliates or sublicensees, in order to operate under or exploit the licenses granted under Article 6 of this Agreement in any country of the Territory, must make payments (including without limitation royalties, option fees or license fees) to one or more third parties to obtain a license or similar right in the absence of which the Licensed Products or Licensed Compound could not legally be manufactured or sold in such country, BM may deduct from royalties thereafter payable to GI Net Sales earned in such country only during the calendar year period in which BM makes such payment \*

Article 8. MANUFACTURING RIGHTS

8.1 Pre-Commercialization Rights. GI and/or its affiliates shall exclusively manufacture for and supply to BM the entire amount of Licensed Compound required by BM for pre-clinical developments, clinical trials or other non-commercial uses prior to commercialization of Licensed Products. Licensed Compound used for pre-clinical developments, clinical trials or other non-commercial uses prior to commercialization will be supplied by GI to BM as outlined in Schedule F.

A 73240

8.2 Commercial Supply of Licensed <sup>Compound</sup> ~~Products~~. As long as BM has not exercised its right to manufacture the Licensed Compound, GI and/or its Affiliates shall supply BM exclusively with all its requirements of Licensed Compound in a quantity agreed upon in a separate supply agreement. The supply price shall not exceed \*

If GI shall at any time agree to supply Licensed Compound to any third party outside the Territory on terms and conditions more favorable to such third party than the terms and conditions hereunder, GI shall notify BM of such more favorable terms and BM shall, upon written notice to GI within 30 days after its receipt of GI's notice, be entitled to substitute the entire terms and conditions contained in such more favorable transaction for the comparable terms and conditions hereof.



*Handwritten initials: MS, BS*

8.3 Technical Assistance. GI shall, upon request from BM, make available to BM the Principal Investigator (to the extent available) and members of the technical staff of GI assigned to the Project in order to assist BM in the scaling-up of operations and in the start up of BM's commercial production facilities for the manufacture of the requirements of BM and its Affiliates of Licensed Compounds, subject to the manufacturing rights granted to GI pursuant to Section 8.1. Details of technical assistance shall be agreed upon separately no later than 12 months prior to the date that GI exercises its right to manufacture pursuant to Section 8.1 above.

GI shall provide to BM detailed documentation on the processing conditions it uses for the production of Licensed Compound, following the latest standard applicable to the production at that time which shall include the cell line to be used, cell culture medium composition, environmental conditions for cell culture such as pH and temperature, purification processes as well as all specifications and quality control descriptions following the latest GLP-GMP

standard ap  
To ass  
standards,  
constructio  
for regulat  
Licensed Co  
GI sha  
not specif  
Compounds,  
manufacture  
to render  
BM hereunde  
In re  
all direc  
transporta

9.1  
full exec  
unless mod  
hereof fo  
sale and/  
license of

9.2  
entitled  
other Par  
default o  
remedy an  
the non-t  
pursuant  
of any of

BM  
forthwith  
in  
the  
cli  
or  
arr  
is  
the  
vol

9.3  
cit

A 73241



As long as the Licensee exclusively provides a quality supply price

ed Compound terms and the terms such more to GI given be entitled contained in terms and

quest for or (to the staff of GI e scale-up commercial requirements ect to the ction 8.1 eed upon ta that e ction 8.1

on on the e Licensed to GI's line of Ironmental. ature and ctions and GMP

standard applicable at the date of transfer. To assist BM in reaching quality control compliance at GI standards, GI shall make available to BM facility design and construction data as well as aseptic techniques and programs for regulating compliance which apply to the production of Licensed Compound.

GI shall not be responsible for assisting BM with matters not specifically related to the manufacturing of Licensed Compounds, such as matters generally practiced in the manufacture of biological materials. GI shall not be required to render more than \* man hours of technical assistance to BM hereunder, unless otherwise agreed upon by the Parties.

In rendering such assistance GI shall be reimbursed for all direct and reasonable expenses such as hotel, transportation and meals incurred by GI personnel.

Article 9. TERMINATION

9.1 Term. This Agreement shall become effective upon full execution and shall continue in full force and effect unless modified or terminated in accordance with any provision hereof for a period of \* years as of BM's first commercial sale and/or the last patent to expire or until expiry of the license granted pursuant to Art. 6 whichever is longer.

9.2 Termination for Breach. Each Party shall be entitled to terminate the Agreement by written notice to the other Party in the event that the other Party shall be in default of any of its obligations hereunder, and shall fail to remedy any such default within 60 days after notice thereof by the non-breaching Party. Upon termination of this Agreement pursuant to this Section 9.2, neither Party shall be relieved of any obligations incurred prior to such termination.

BM reserves the right to terminate this Agreement forthwith,

in the event that the use of the Licensed Product has in the opinion of BM a negative risk/benefit value in clinical use

or GI shall become bankrupt, insolvent or make any arrangement with its creditors and/or a winding up order is made and/or if the business of GI shall be placed in the hands of a Receiver, Assignee or Trustee whether by voluntary act of GI or otherwise.

9.3 Termination by GI of Exclusivity. In the event that either

- a) BM fails to make any required minimum royalty payment within 30 days of the date such payment is due, or

Handwritten signature/initials

A 73242



- b) BM fails to comply with Section 2.8 of Agreement, and
- c) BM fails to remedy any such default within 30 days after written notice thereof by GI, then upon written notice provided by GI:

  - (i) GI shall receive from BM non-exclusive license in and to BM's Know-how, technology (as described in Section 5.2), animal and cell data, and to such other information in its possession that GI may require in order to obtain approval of the applicable Government Regulatory Agencies;
  - (ii) All licenses granted herein by GI to BM shall become non-exclusive; and
  - (iii) All other terms and conditions of this Agreement not inconsistent with this Section 9.3, shall remain in effect, provided however

\*

9.4 Survival of Obligations;

Return of Confidential Information. Notwithstanding any termination of this Agreement, the obligations of the Parties with respect to the protection and non-disclosure of Confidential Information shall survive and continue to be enforceable. Upon any termination of this Agreement pursuant to Sections 9.2, each Party shall promptly return to the other Party all written Confidential Information, and all copies thereof, of the other Party.

Article 10. MISCELLANEOUS

10.1 Product Liability Indemnification.

- a) GI agrees to defend BM, its agents, directors, officers and employees at GI's cost and expense, and will indemnify and hold BM harmless, its agents, directors, officers and employees, from and against any and all losses, costs, damages, fees or expenses arising out of or in connection with actual or alleged injury, damage or other consequence occurring to any person as a result of any negligence of GI in the manufacture of licensed Compound whether claimed by reason of breach of warranty,

10.2  
publicity,  
or oral,  
existence  
prior writ  
required

10.3  
rights of  
Party wit  
except to  
the busin  
or other

10.4  
and inte  
controver  
Agreement  
to arbit  
language  
Commerce  
court.  
exclusiv  
Each  
giving  
Intentio  
Party fa

2.8 of this  
t within 30  
by GI,  
by GI to BM  
usive rights  
hology (as  
l and human  
ion in BM's  
in order to  
a Government

to BM shall:

ns of the  
this Section  
ed however.

withstanding  
ons of the  
losure of  
ine to be  
nt pursuant  
to the other  
all copies

directors,  
cost and  
d BM  
fficers and  
v and all  
r expenses  
with ne  
or other  
erson as  
II in the  
ed whether  
nter,

negligence, product defect, or otherwise, and regardless of the form in which any such claim is made. In the event of any such claim against BM, or any agent, director, officer or employee by any party, BM shall promptly notify GI in writing of the claim, and GI shall manage and control at its sole expense the defense and the claim and its settlement. BM shall cooperate with GI and may at its options and expense, be represented in any such action or proceeding. GI shall not be liable for any litigation costs or expenses incurred by BM without GI's written authorization.

(b) BM undertakes to indemnify and hold GI harmless from and defend against any and all claims, actions or threat of action based upon or related to or arising from omissions, negligence or any wrongdoing of BM in the performance of this Agreement or the manufacture of the Licensed Compound and the manufacture, sales and distribution of the Licensed Products. BM shall bear the cost arising in connection herewith.

10.2 Publicity. Neither Party shall originate any publicity, news release or other public announcement, written or oral, relating to this Agreement, the Project or the existence of an arrangement between the Parties, without the prior written approval of the other Party except as otherwise required by law.

10.3 Assignment. Neither this Agreement nor any of the rights or obligations hereunder may be assigned by either Party without the prior written consent of the other Party, except to a party which acquires all or substantially all of the business of the assigning Party by merger, sale of assets or otherwise.

10.4 Governing Law. This Agreement shall be governed by and interpreted in accordance with Swiss Law. Any dispute, controversy, or claim arising out of or relating to this Agreement which cannot be amicably settled shall be referred to arbitration held in Zurich/Switzerland in the English language in accordance with the rules of the Chamber of Commerce of Zurich/Switzerland to the exclusion of any other court. The Court of Arbitration shall decide finally and exclusively.

Each Party shall name one arbitrator within 30 days of giving or receiving respectively written notice of the intention to apply to the Court of Arbitration. If either Party fails to designate its arbitrator within the stated

period of time, such arbitrator will be appointed by the President of the Zurich Chamber of Commerce, who shall appoint the Chairman of the Court of Arbitration as well as two additional arbitrators proposed by the President of the Chamber of Commerce of Zurich/Switzerland, having regard to the recommendations made by the previously named arbitrators. The acceptance of the mandate by the Zurich Chamber of Commerce will be obtained by BM at BM's cost and shall serve as Schedule H of this Agreement.

10.5 Force Majeure. In the event that either Party is prevented from performing or is unable to perform any of its obligations under this Agreement due to any act of God, fire, casualty, flood, war, strike, lockout, failure of public utilities, injunction or any act, exercise, assertion or requirement of governmental authority, including any governmental law, order or regulation or any preliminary injunction permanently or temporarily prohibiting or reducing the level of research, development or production under hereunder or the manufacture, use or sale of Licensee's Products; epidemic, destruction of production facilities; riots, insurrection, inability to procure or use materials, labor, equipment, transportation or energy sufficient to meet experimentation or manufacturing needs; or any other cause beyond the reasonable control of the Party invoking this Section 10.5 if such Party shall have used its best efforts to avoid such occurrence, such Party shall give notice to the other Party in writing promptly, and thereupon the affected Party's performance shall be excused and the time for performance shall be extended for the period of delay due to inability to perform due to such occurrence.

10.6 Waiver. The waiver by either Party of a breach or default of any provision of this Agreement by the other Party shall not be construed as a waiver of any succeeding breach of the same or any other provision, nor shall any delay or omission on the part of either Party to exercise or assert itself of any right, power or privilege that it has or may have hereunder operate as a waiver of any right, power or privilege by such Party.

10.7 Notices. Any notice or other communication in connection with this Agreement must be in writing and is to be sent by certified mail, return receipt requested, and shall be effective when delivered to the addressee at the address listed below or such other address as the addressee shall specify in a notice actually received by the addressor.

If t  
Gene  
87 C  
Camb  
U.S.  
Atte

If t  
Boeh  
Sand  
D-68  
Fede  
Atte

10.8  
constitut  
other Par  
any purpos  
employee  
its serv  
discretio  
or omis  
authority  
in any  
Party.

10.9  
hereto (A  
Agreement  
the Part  
supersede  
thereto.  
provisio  
signed b  
duly auth

10.  
are for  
consider

10.  
this Agr  
be unenfo  
law of  
remaining  
obligatio  
the  
held to

nted by the  
o shall also  
as well as  
ident of the  
ng regard to  
rators.  
h Chamber of  
shall serve

her Party is  
m any of the  
of God, fire,  
e of public  
assertion of  
cluding any  
preliminary  
or reducing  
uction work  
of licensed  
facilities.  
e materials.  
ient to meet  
other cause  
nvoking this  
st efforts to  
otice to the  
the affected  
e time for  
of delay is

a breach of  
other Party  
ng breach of  
ny delay is  
se or avail  
has or not  
it, power is

unication  
ng and if  
d, and shall  
the address  
be shall have  
ressor.

If to GI:

Genetics Institute, Inc.  
87 CambridgePark Drive  
Cambridge, Massachusetts 02140  
U.S.A.  
Attention: President

If to BM:

Boehringer Mannheim GmbH  
Sandhofer Strasse 116  
D-6800 Mannheim 31  
Federal Republic of Germany  
Attention: Geschaeftsfuehrung

10.8 No Agency. Nothing herein shall be deemed to constitute either Party as the agent or representative of the other Party, or both Parties as joint ventures or partners for any purpose. GI shall be an independent contractor, not an employee or partner of BM, and the manner in which GI renders its services under this Agreement shall be within GI's sole discretion. Neither Party shall be responsible for the acts or omissions of the other Party, and neither Party will have authority to speak for, represent or obligate the other Party in any way without prior written authority from the other Party.

10.9 Entire Agreement. This Agreement and the Schedules hereto (which Schedules are deemed to be a part of this Agreement for all purposes) contain the full understanding of the Parties with respect to the subject matter hereof and supersede all prior understandings and writings relating thereto. No waiver, alteration or modification of any of the provisions hereof shall be binding unless made in writing and signed by the Parties by their respective officers thereunto duly authorized.

10.10 Headings. The headings contained in this Agreement are for convenience of reference only and shall not be considered in construing this Agreement.

10.11 Severability. In the event that any provision of this Agreement is held by a court of competent jurisdiction to be unenforceable because it is invalid or in conflict with any law of any relevant jurisdiction, the validity of the remaining provisions shall not be affected, and the rights and obligations of the Parties shall be construed and enforced as if the Agreement did not contain the particular provisions held to be unenforceable.

A 73246

10.12 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their successors and permitted assigns.

10.13 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.


IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as a sealed instrument in their names by their properly and duly authorized officers or representatives as of the date first above written.


Mannheim

Cambridge,


BOEHRINGER MANNHEIM GMBH  
GmbH.

GENETICS INSTITUTE, INC.

  
Dr. Abshagen Prof. Dr. Abshagen

  
Gabriel Schmerqel

Witness De:

Witness:  
GENETICS INSTITUTE  
Gabriel Schmerqel  
BOEHRINGER MANNHEIM  


be  
reto

SCHEDULE A

BENCHMARKS

in  
an  
and

Description

Payment (in U.S. \$)

this  
times  
or

\*

SC.

ated:

INSTITUTE, INC.

*David Schumaker*

MANHEIM GMBH

*[Signature]*

*[Signature]*

*[Handwritten notes]*

*[Handwritten notes]*

A 73248

SCHEDULE R  
TERRITORY



Acknowledged:

GENETICS INSTITUTE, INC.

By: Gabriel Schmepp

ROEHRINGER MANNHEIM GMBH

By: [Signature]

Democratic  
Slovakia

USA

USA

Union (USA)

Acknowledged:

GENETICS INSTITUTE

Gabriel Schmepp

ROEHRINGER MANNHEIM

[Signature]

[Handwritten initials]

A 73249

SCHEDULE C

COMECON COUNTRIES

Democratic Republic  
Czechia

on (USSR)

ated:

INSTITUTE, INC.

Samuel Schumacher

MANNHEIM GMBH

*[Handwritten signature]*

*[Handwritten initials]*

*[Handwritten initials]*

A 73250

A073250

AM-ITC 00119923



SCHEDULE D  
MINIMUM ROYALTY



Acknowledged:

GENETICS INSTITUTE, INC.

By: Gabriel Schmeigel

BOEHRINGER, MANNHEIM GMBH

By: [Signature]

Acknowledged:  
GENETICS INSTITUTE  
Gabriel Schmeigel  
BOEHRINGER, MANNHEIM GMBH  
[Signature]

A 73251

SCHEDULE E

\*

*Wes  
lin  
Bo*

dated:

INSTITUTE, INC.

*Wolfgang Schmeigel*

MANHHEIM GMBH

*Wolfgang Schmeigel*

*Wes  
lin  
Bo*

*Wes  
lin  
Bo*

A 73252

SCHEDULE F

PRE-COMMERCIALIZATION SUPPLY OF LICENSED COMPOUND



Acknowledged:

GENETICS INSTITUTE, INC.

By: Gabriel Scherer

ROEHRINGER MANNHEIM GMBH

By: [Signature]

Acknowledged:

GENETICS INSTIT

Gabriele

ROEHRINGER MANN

[Signature]

[Signature]

A 73253

SCHEDULE G  
PRODUCTION SCHEDULE



Witnessed:

BY INSTITUTE, INC.

*Abuwal Schumpel*

BEER MANNHEIM GMBH

*[Handwritten signature]*

*Bö*

*[Handwritten signature]*  
*u.c*

A 73254